Background Tissue-type plasminogen activator (TPA) is the principal activator of plasminogen. Since hemostasis in the microcirculation of allografts is a well-recognized complication of transplantation, we asked (1) whether the distribution and amount of cellular TPA in biopsies of transplanted human hearts are associated with fibrin deposits in and around the microcirculation, (2) whether such changes involve the physiological inhibitors of TPA and plasmin, and (3) whether the presence of these activators and inhibitors of fibrinolysis in tissue is correlated with clinical outcome.
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Methods and Results
We immunocytochemically quantified the presence of fibrin, plasmin, TPA, and the TPA inhibitor PAI-1 in 938 biopsies from 68 consecutive cardiac allografts over a 54-month period. The localization, distribution, and quantification of TPA in arteriolar smooth muscle cells revealed that 35 of the 68 allografts maintained vascular TPA reactivity consistent with time-zero biopsies of autologous donor hearts: this was designated as the normal TPA group. In contrast, 33 of the 68 allografts significantly lost vascular TPA reactivity compared with time-zero biopsies of autologous donor hearts: this was designated as the depleted TPA group. Analysis of sequential biopsies from both groups during 54 months revealed that the mean cumulative quantitative TPA value for the normal TPA group was 1.0±0.01, whereas the depleted TPA group value was 1.9±0.02 (P=.0001), and the mean cumulative quantitative fibrin value for the normal TPA group was 1.0±0.01, whereas the depleted TPA group value was 1.5±0.05 (P=.0001). Biopsies of allografts in the depleted TPA group contained endothelial reactivity for TPA-PAI-1 complexes, whereas biopsies from the normal TPA group did not. Plasmin-associated molecules were rarely identified in biopsies of the normal TPA group but were present in the depleted TPA group, and the fibrin-to-plasmin ratio in the normal TPA group always was less than the fibrin-to-plasmin ratio in biopsies from the depleted TPA group. Analysis of demographic and risk factors revealed no significant differences between patients in the normal and depleted TPA groups, but none of the 35 patients in the normal TPA group died or were retransplanted, and 13 of the 33 patients in the depleted TPA group died or required retransplantation (P=.0001).
Conclusions Time Cholesterol (normal, 165 to 240 mg/dL) and triglycerides (normal, 10 to 200 mg/dL) were measured by enzymatic methods in spectrophotometry.26 Donor-specific cytotoxic antibodies and major histocompatibility complex classes I (HLA-A and HLA-B) and II (HLA-DR) immunophenotyping were done by microlymphocytotoxicity assays. 27 Donor hearts were perfused with Stanford cardioplegia solution before transport. Mean ischemic time for the 68 donor hearts was 130.8±6.4 minutes. Patients were followed with serial biopsies performed during cardiac catheterization. Endomyocardial biopsies were obtained from the right ventricle of all hearts before and after transplantation. Time-zero control biopsies were obtained before perfusion with recipient blood. Biopsies were taken on the 10th postoperative day, every 2 weeks during the first 2 months, and at 3, 4.5, 6, 9, and 12 months and every 6 months thereafter. Cellular infiltrates were evaluated by conventional light microscopy according to the International Society for Heart Transplantation,28 and only major rejection episodes (grades 3 and 4) were considered rejections. Biopsies with cellular infiltrates during the follow-up of a rejection episode were considered part of the same rejection period.
Immunocytochemistry
Biopsies were snap frozen in liquid nitrogen and stored at -20°C. The interval between biopsy and snap-freezing was <30 minutes. Thin sections (4 
Antibodies and Control Experiments
The sources, specificities, and dilutions of antibodies are detailed in Table 1 . Each experiment included antibody, PBS, and conjugate controls. These were done at room temperature by exposure of cryostat sections to only PBS, isotype-matched irrelevant antibody, or conjugate. The irrelevant rabbit antibody was anti-human IgE (Dakopatts, Glostrup, Denmark), and mouse irrelevant monoclonals were IgGl anti-cytomegalovirus early antigen (Chemicon, Temecula, Calif) and IgG2a anti-Epstein-Barr virus capsid antigen (Chemicon). The dilution for each antibody was two serial dilutions before end point titration.29 Antibodies were ultracentrifuged at 100 OOOg at 4°C for 1 hour to remove complexes and aggregates, and monthly titrations and ultracentrifugations were done for each antibody. The reactivity of anti-TPA was removed by absorption with recombinant TPA from Genentech (San Francisco, Calif), confirming specificity of the antibody. 30 
Microscopy
Tissue preparations were studied by epi-illumination in a Leitz Orthoplan microscope fitted with interference optics and an HBO-100 mercury-arc lamp.3' The epi-illuminator contained an 1-3 type FITC filter complex consisting of a 450-to 490-nm excitation filter with a 510-nm dichroic mirror and a 515-nm barrier filter allowing wavelengths >515 nm to pass and an N2.1 type RITC filter complex consisting of a 515-to 560-nm excitation filter with a 580-nm dichroic mirror and a 580-nm barrier filter allowing wavelengths >580 nm to pass. A Leitz camera that contained ASA 200 daylight 35-mm Ektachrome film was used.
Quantification of Immunocytochemical Results
Immunocytochemical reactivities were graded for statistical purposes from coded photomicrographs of equivalent magnifications. These were projected from the same distance in a darkened room and scored by three investigators unaware of the origins of the biopsies, as previously reported.2,4,7,8 11This quantification scheme was used for TPA, fibrin, and plasmin, as follows. (1) For TPA, arteriolar smooth muscle cells (SMCs) were identified by use of monoclonal antibody (Mab) to a-smooth muscle cell actin.7"1 Arterioles the size of one myocardial cell or smaller (10 to 15 per biopsy section) were evaluated for TPA and scored. A score of 1 was reactivity of all arteriolar SMCs with Mab to TPA. A score of 2 was reactivity only of isolated SMCs. To confirm that TPA reactivity was in SMCs, reactions were photographed and the sections were stained with hematoxylin and eosin, or an adjacent serial section was reacted with Mab to a-smooth muscle actin.7"1 (2) Fibrin was identified by use of a Mab to the ,-chain N-terminal neotope present on fibrin but not fibrinogen.32 Biopsies were evaluated immunocytochemically for fibrin by use of a grading system in which no fibrin deposits or fibrin deposits in <10% of the capillary network was assigned a grade of 1. To determine the percentage of reactive vessels, double-antibody experiments were done with polyclonal antibody to von Wille ported TPA in cultured endothelial cells (see Reterence 23 for review), it is necessary to stress that none of the 68 time-zero biopsies studied in this investigation contained TPA-reactive endothelial cells. Thus, time-zero hearts were found not to manifest immunocytochemical evidence of activated hemostasis or fibrinolysis, and TPA was identified only in arteriolar SMCs.
Data From Allograft Biopsies
All biopsies (n-938) were prospectively studied for TPA, fibrin, and the physiological inhibitors of TPA and plasmin. Evaluation of biopsies for TPA revealed two types of distribution within SMCs: One was indistinguishable from time-zero hearts (Fig la) and was designated as the normal TPA type. The second was significantly depleted of TPA compared with time-zero hearts (Fig lb) and was designated as the depleted TPA type. Serial sections using Mab to a-SMC actin showed that there was no depletion of arteriolar SMCs. These distributional types were identified in early biopsies and persisted. Analysis of the distribution, localization, and quantification of TPA in all 938 biopsies revealed that 35 of the 68 patients maintained normal TPA throughout the duration of the study, and 33 of the 68 allografted hearts developed depleted TPA within the first month after transplantation (Table 2) , although the time-zero biopsies from these hearts were normal.
Evaluation of the distribution, localization, and quantification of fibrin in the 938 biopsies revealed that samples from allografts with normal TPA contained little or no fibrin (Fig 2a) , whereas fibrin was identified in samples from allografts with depleted TPA (Fig 2b) .
These deposits were localized to the microcirculation, often extending into interstitial spaces (Fig 2b) . Quantification of these deposits revealed that the 35 allografts with consistently normal TPA had a mean cumulative fibrin value of 1.0±0.01, and the 33 allografts with consistently depleted TPA had a mean cumulative fibrin value of 1.5+0.05 (P=.0001), as seen in Table 2 . When the TPA and fibrin data from the normal and depleted groups were examined mathematically for temporal associations with fibrin deposits, it was found that allografts with normal TPA were consistently associated with less fibrin deposition than were allografts with depleted TPA (Fig 3) . Patients with depleted TPA and fibrin within the microcirculation who managed to survive showed a recovery of the arteriolar TPA associated with an absence of fibrin (Fig 3) .
Evaluation of the distribution, localization, and quantification of plasmin in the 938 biopsies was done with an antibody to the a2PI that binds to the enzyme active site and an antibody to the neotope formed by the plasmin-a2PI complex. Vascular lesions that contained fibrin deposits also reacted with antibody to ca2PI, but fibrin-reactive areas in biopsies with depleted TPA did not contain a2PI (Fig 4) . Fibrin-to-a2PI ratios revealed that the 35 patients with normal TPA had a mean cumulative fibrin-to-a2PI ratio of 1.06±0.03, and the 33 patients with depleted TPA had a mean cumulative ratio of 1.25±0.03 (P=.0001), as shown in Table 2 To determine the functional status of TPA in allografts, biopsies were studied with Mab to the principal inhibitor of TPA, PAI-1. Two different Mabs to PAI-1 were used. One of these reacted with a neotope of PAI-1 that is exposed when PAI-1 is complexed with TPA, thus allowing the identification of nonfunctional TPA molecules. The other Mab reacted with uncomplexed PAI-1. Antibody to the neotope of TPA-complexed PAI-1 did not react with biopsies from the 35 allografts that contained normal TPA in arteriolar SMCs and no fibrin (Fig 5a) . As stated earlier, none of these allografts had TPA-reactive endothelium, an example of which is shown in Fig la. However, the 33 allografts that manifested microvascular fibrin and depleted arteriolar SMC TPA frequently contained endothelium that reacted with antibody to TPA and to the neotope of TPA-complexed PAI-1, allowing the in situ identification of nonfunctional TPA molecules (Fig Sb) Both hearts removed for retransplantation and 8 of the 11 allografts from patients who died were studied. Immunocytochemical data from these organs were not different; thus, they are reported together as failed allografts. The arteriolar SMC TPA was restricted to sparse and isolated SMCs and usually was absent. Diffuse deposits of fibrin were found in the microcirculation, in the interstitium, and around and within myocardial cells (Fig 6) . The microcirculation of these hearts did not react with antibodies to either a2PI or the plasmin-a2PI neotope. suggesting depressed fibrinolysis. This was supported by calculations that showed maximum fibrin-to-a PI ratios. The immunological identification of abundant fibrin and the absence of plasmin within the microcirculation of these failed allografts was associated with endothelial reactivitv for TPA and TPA-PAI-1 complexes in the same vessels.
Results of reacting adjacent serial sections with Mab to a-smooth muscle actin or staining adjacent serial sections with hematoxylin and eosin revealed that the reactive endothelial cells were associated with capillaries, venules, or veins and not with arteries or arterioles. A comparative analysis of these findings with data from time-zero biopsies and with data from clinicallv stable and clinically unstable allograft recipients is given in Table 4 .
The failed allografts were studied by light microscopy.
This revealed that four had acute ischemic changes compatible with recent myocardial infarctions. and one of these had a superimposed bacterial infection: three had moderate to severe lvmphocytic infiltration with acute myocardial infarctions and severe coronary arterv disease:
one had severe coronary artery disease with interstitial fibrosis; and two had no histological abnormalities. Discussion The correlation of immunocytochemical findings with clinical outcome of the 68 patients in this studx was telling. Most compelling was the finding that 39% of the 33 patients with consistently depleted arteriolar SMC TPA in their allograft biopsies died or required retransplantation. and none of the 35 patients with consistently normal arteriolar SMC TPA in their allograft biopsies died or required retransplantation. However, a more important finding would not have emerged if the patients had not been studied prospectively over the 54-month period. This is the observation that the status of arteriolar SMC TPA in biopsies obtained during the first postoperative month could be used to classify patients into normal and depleted TPA groups and that the long-term outcome for the depleted TPA group was poor. It is puzzling that such a significant finding declared itself so early in the course of transplantation, and it is unfortunate that no other laboratory measurement assisted in the identification of these high-risk patients.
Three observations in this study reached high levels of significance when biopsies with normal arteriolar SMC TPA were compared with biopsies depleted of TPA. Indeed, recent studies of experimental models of TPA synthesis have revealed that the production of this molecule is altered after specific manipulations of cells in vitro. For example, cells grown in the presence of gonadotropins, gonadotropin-releasing hormone, or certain growth factors produce TPA mRNA,60,61 but the effects are transient, they involve different intracellular pathways, and some of the same growth factors promote synthesis of PAI-1 mRNA.61 In addition, cells grown in the presence of retinoids also increase TPA mRNA synthesis and TPA secretion,2262 and these reactions are not accompanied by increased PAI-1 synthesis.22 Alternatively, recent experimental63,64 and clinical65,66 data indicate that heparin augments the ability of TPA to exert its catalytic function in fibrinolysis. Heparin has the additional advantage of inhibiting the proliferation of SMCs,67 the migration of which accounts for some of the lesions found in transplant-induced vasculopathies. 1 ,68 Thrombogenesis is controlled physiologically by the natural anticoagulant pathways. 9 The reactions of these molecules normally range from direct inhibition of endothelial tissue factor by the tissue factor pathway inhibitor69 to the neutralization of thrombin by antithrombin III and the conversion of thrombin to an anticoagulant by thrombomodulin. 70 There is very little information about the roles of most of the natural anticoagulant pathways in organ allografts,3.5,10 70,71 but it is known that the endothelial heparan sulfate proteoglycan-antithrombin III pathway is poorly represented in cardiac allografts with significant vascular disease compared with matched time-zero biopsies.28,9,11.5 In these cases, the loss of thromboresistance as measured by the appearance of fibrin was correlated with the loss of immunologically detectable antithrombin III from endothelial plasma membranes, and a survival advantage was reported in allograft recipients whose biopsies demonstrated the presence of antithrombin III on capillary endothelial cells.9 Inasmuch as these studies also reported no consistent correlation with cellular infiltrates,8 15 we propose that metabolically perturbed natural anticoagulant pathways allow thrombin to be generated and that the uninhibited thrombin mediates fibrin deposition, which augments thrombin-driven secretion and subsequent depletion of TPA from its cellular reservoirs.
